Industry
The approval is major step forward in the fight against recurrent C. diff infection.
Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.
Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…
Industry
Sponsored by
In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.
Industry
Sponsored by
Probiotic intervention in the gut–prostate axis with novaPROX combo: insights from an in vitro study
The study published on Foods Journal researched the mechanisms of action of Probionova's novaPROX product using a 3D intestinal barrier model and a co-culture prostatic model.
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.
Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.
The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.
The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
